Anne O’Donnell

5.3k total citations
51 papers, 2.2k citations indexed

About

Anne O’Donnell is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Emergency Medical Services. According to data from OpenAlex, Anne O’Donnell has authored 51 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 11 papers in Emergency Medical Services. Recurrent topics in Anne O’Donnell's work include Cystic Fibrosis Research Advances (13 papers), Pediatric health and respiratory diseases (11 papers) and Cancer Treatment and Pharmacology (6 papers). Anne O’Donnell is often cited by papers focused on Cystic Fibrosis Research Advances (13 papers), Pediatric health and respiratory diseases (11 papers) and Cancer Treatment and Pharmacology (6 papers). Anne O’Donnell collaborates with scholars based in United Kingdom, United States and New Zealand. Anne O’Donnell's co-authors include Ian Judson, Florence I. Raynaud, Paul Workman, Andrew Dravnieks, Michelle Scurr, Daniel Rea, N. Shand, Katharine Hazell, Laura K. Simmons and Simon Pacey and has published in prestigious journals such as Journal of Clinical Oncology, Environmental Science & Technology and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Anne O’Donnell

50 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anne O’Donnell United Kingdom 15 1.0k 885 497 229 227 51 2.2k
Aili L. Lazaar United States 30 731 0.7× 827 0.9× 355 0.7× 144 0.6× 168 0.7× 52 3.0k
Fei Wang China 26 1.0k 1.0× 1.1k 1.2× 1.0k 2.1× 202 0.9× 404 1.8× 200 3.3k
Xiong Chen China 19 667 0.7× 853 1.0× 450 0.9× 245 1.1× 417 1.8× 80 1.9k
R. Berges Germany 28 1.3k 1.2× 563 0.6× 275 0.6× 162 0.7× 187 0.8× 90 2.6k
Yoshinori Inagaki Japan 28 388 0.4× 1.1k 1.2× 416 0.8× 402 1.8× 345 1.5× 125 2.7k
Yasuhito Kobayashi Japan 24 392 0.4× 815 0.9× 700 1.4× 169 0.7× 328 1.4× 85 2.2k
Shuan Rao China 20 412 0.4× 1.5k 1.7× 465 0.9× 362 1.6× 563 2.5× 50 3.9k
Feng Wu China 30 375 0.4× 1.1k 1.3× 461 0.9× 160 0.7× 577 2.5× 60 2.5k
Kouji Izumi Japan 29 1.4k 1.4× 888 1.0× 985 2.0× 181 0.8× 454 2.0× 219 3.4k
Yoshihiko Ikeda Japan 28 272 0.3× 675 0.8× 258 0.5× 308 1.3× 135 0.6× 157 3.0k

Countries citing papers authored by Anne O’Donnell

Since Specialization
Citations

This map shows the geographic impact of Anne O’Donnell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne O’Donnell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne O’Donnell more than expected).

Fields of papers citing papers by Anne O’Donnell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne O’Donnell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne O’Donnell. The network helps show where Anne O’Donnell may publish in the future.

Co-authorship network of co-authors of Anne O’Donnell

This figure shows the co-authorship network connecting the top 25 collaborators of Anne O’Donnell. A scholar is included among the top collaborators of Anne O’Donnell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne O’Donnell. Anne O’Donnell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Flume, Patrick A., David E. Griffith, James D. Chalmers, et al.. (2020). Development of Drugs for Nontuberculous Mycobacterial Disease. CHEST Journal. 159(2). 537–543. 14 indexed citations
3.
Chalmers, James D., David Cipolla, Bruce Thompson, et al.. (2020). Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies. European Respiratory Journal. 56(4). 2000110–2000110. 35 indexed citations
4.
5.
Jackson, Christopher, Katrina Sharples, Paul Thompson, et al.. (2014). Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study. BMC Cancer. 14(1). 737–737. 3 indexed citations
6.
Barker, Alan R., Anne O’Donnell, Philip J. Thompson, et al.. (2013). Two phase 3 placebo-controlled trials of aztreonam lysine for inhalation (AZLI) for non-cystic fibrosis bronchiectasis (NCFB). European Respiratory Journal. 42(Suppl 57). P4136–P4136. 10 indexed citations
7.
Boyer, José L., Melissa Johnson, John H. Ansede, et al.. (2013). P-321, a Novel Long-Acting Epithelial Sodium Channel (ENaC) Blocker for the Treatment of Dry Eye Disease. Investigative Ophthalmology & Visual Science. 54(15). 957–957. 2 indexed citations
8.
Gleeson, Peggy, et al.. (2013). Qualitative Assessment of Component-Specific, Fall-Risk Screening Procedures to Create a Fall Risk Screening Form. Journal of Geriatric Physical Therapy. 36(4). 155–161. 2 indexed citations
9.
Alder, Jeff, Robert C. Wilson, Tobias Welte, et al.. (2011). Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis. European Respiratory Journal. 38(Suppl 55). 1930–1930. 4 indexed citations
10.
11.
O’Donnell, Anne, et al.. (2009). Metabolism of methyltestosterone in the greyhound. Rapid Communications in Mass Spectrometry. 23(5). 713–721. 12 indexed citations
12.
Benson, Charlotte, Jeff White, Johann S. de Bono, et al.. (2006). A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. British Journal of Cancer. 96(1). 29–37. 221 indexed citations
13.
O’Donnell, Anne, Anwar R. Padhani, Carmel Hayes, et al.. (2005). A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. British Journal of Cancer. 93(8). 876–883. 60 indexed citations
14.
Fonda, Stephanie J., et al.. (2005). Age, Hormones, and Cognitive Functioning Among Middle-Aged and Elderly Men: Cross-Sectional Evidence From the Massachusetts Male Aging Study. The Journals of Gerontology Series A. 60(3). 385–390. 101 indexed citations
15.
Banerji, Udai, Anne O’Donnell, Michelle Scurr, et al.. (2005). Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies. Journal of Clinical Oncology. 23(18). 4152–4161. 377 indexed citations
16.
O’Donnell, Anne, Ian Judson, Mitch Dowsett, et al.. (2004). Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. British Journal of Cancer. 90(12). 2317–2325. 300 indexed citations
17.
Harries, Mark, Anne O’Donnell, Michelle Scurr, et al.. (2004). Phase I/II study of DHA–paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours. British Journal of Cancer. 91(9). 1651–1655. 20 indexed citations
18.
19.
Barker, Alan F., Stanley B. Fiel, Mark H. Gotfried, et al.. (2000). Tobramycin Solution for Inhalation Reduces Sputum Pseudomonas aeruginosa Density in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 162(2). 481–485. 239 indexed citations
20.
O’Donnell, Anne, et al.. (1988). Pulmonary Complications of Percutaneous Nephrostomy and Kidney Stone Extraction. Southern Medical Journal. 81(8). 1002–1005. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aili L. Lazaar Breakdown of academic impact, for papers by Fei Wang Breakdown of academic impact, for papers by Xiong Chen Breakdown of academic impact, for papers by R. Berges Breakdown of academic impact, for papers by Yoshinori Inagaki Breakdown of academic impact, for papers by Yasuhito Kobayashi Breakdown of academic impact, for papers by Shuan Rao Breakdown of academic impact, for papers by Feng Wu Breakdown of academic impact, for papers by Kouji Izumi Breakdown of academic impact, for papers by Yoshihiko Ikeda
Rankless by CCL
2026